M&A

Abbott's choice: acquire more businesses now or pay later
Abbott's choice: acquire more businesses now or pay later
Modern Healthcare
Abbott Labs
M&A
devices
Flag link:
Demand For Gene Therapies To Prompt Surge In Pharma M&A
Demand For Gene Therapies To Prompt Surge In Pharma M&A
Forbes
gene therapy
M&A
Bluebird Bio
Sangamo Therapeutics
Flag link:
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine
Xconomy
Roche
Foundation Medicine
M&A
Flag link:
Evotec seals deal for Sanofi’s infectious disease unit
Evotec seals deal for Sanofi’s infectious disease unit
Fierce Biotech
Evotec
Sanofi
M&A
infectious diseases
Flag link:
Could More M&A Activity in MedTech Be on the Way?
Could More M&A Activity in MedTech Be on the Way?
Medical Devices and Diagnostics Industry
M&A
devices
Flag link:
With Headway in NASH, Madrigal Pharma is Considering Sale
With Headway in NASH, Madrigal Pharma is Considering Sale
BioSpace
Madrigal Pharmaceuticals
M&A
NASH
Flag link:
Stryker dismisses Boston Scientific buyout rumors, sees shares rebound
Stryker dismisses Boston Scientific buyout rumors, sees shares rebound
Mass Device
devices
M&A
Stryker
Boston Scientific
Flag link:
Johnson & Johnson OKs $2B LifeScan sale to Platinum Equity
Johnson & Johnson OKs $2B LifeScan sale to Platinum Equity
Drug Delivery Business News
JNJ
M&A
LifeScan
blood glucose monitoring
devices
Flag link:
Can This Pharma's $14 Billion Bet Succeed?
Can This Pharma's $14 Billion Bet Succeed?
Motley Fool
Pfizer
M&A
Medivation
Xtandi
talazoparib
Flag link:
Alexion snags option to buy neurodegeneration startup Complement
Alexion snags option to buy neurodegeneration startup Complement
Fierce Biotech
Alexion
Complement Pharma
M&A
Flag link:
Is Stryker Trying to Strike a Deal with Boston Scientific?
Is Stryker Trying to Strike a Deal with Boston Scientific?
Medical Devices and Diagnostics Industry
devices
M&A
Boston Scientific
Stryker
Flag link:
Bitterly opposed old guard at Takeda wages a last-ditch fight to block ‘foreign blood’s’ $62B Shire buyout
Bitterly opposed old guard at Takeda wages a last-ditch fight to block ‘foreign blood’s’ $62B Shire buyout
Endpoints
Takeda
Shire
Christophe Weber
M&A
Flag link:
Is There an End in Sight for J&J Divestitures?
Is There an End in Sight for J&J Divestitures?
Medical Devices and Diagnostics Industry
JNJ
M&A
LifeScan
Fortive
devices
Flag link:
Here's Why Illumina, Inc. Stock Gained 13.1% in May
Here's Why Illumina, Inc. Stock Gained 13.1% in May
Motley Fool
Illumina
gene sequencing
Edico Genome
M&A
Flag link:
That big Biogen deal you were waiting for? Keep waiting
That big Biogen deal you were waiting for? Keep waiting
Endpoints
Biogen
Tokyo
thrombolytic agents
acute ischemic stroke
M&A
TMS
TMS-007
Flag link:
J&J gets $2.7 billion offer for sterilization unit from Fortive
J&J gets $2.7 billion offer for sterilization unit from Fortive
Yahoo/Reuters
JNJ
Fortive
M&A
sterilzation
Ethicon
Flag link:
BIO18: Oncology surplus could drive down values
BIO18: Oncology surplus could drive down values
Biopharma Dive
biotech
M&A
Syneos Health
oncology
BIO 2018
Flag link:
Is an Acquisition in Portola Pharmaceuticals' Future?
Is an Acquisition in Portola Pharmaceuticals' Future?
Motley Fool
Portola Pharmaceuticals
M&A
Flag link:
BioCryst Urges Stockholders To Vote For Merger With Idera
BioCryst Urges Stockholders To Vote For Merger With Idera
CP Wire
Biocryst
M&A
Idera
Flag link:
NTC acquires part of Novartis’ ophthalmic portfolio
NTC acquires part of Novartis’ ophthalmic portfolio
GoinPharma
Novartis
NTC
ophthalmology
M&A
Flag link:

Pages